Societal CDMO Announces Appointment of Matt Arens to Board of Directors
2023年8月24日 - 5:04AM
Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract
development and manufacturing organization (CDMO) dedicated to
solving complex formulation and manufacturing challenges primarily
in small molecule therapeutic development, today announced the
appointment of Matt Arens to the company’s board of directors. Mr.
Arens has more than 25 years of experience as a successful
investment professional identifying innovative life science
companies with high growth potential. For
the past 15 years, he solely has managed dedicated health
care portfolios.
Mr. Arens currently serves as chief executive
officer and senior portfolio manager at First Light Asset
Management, a firm he founded in 2013. In this role, he is
responsible for creating and overseeing the firm’s investment
strategies, which are rooted in several core principles including a
commitment to long-term investments designed to capitalize on
inefficiencies within the small-cap equity market. Previously, he
served as president and senior portfolio manager at Kopp Investment
Advisors, where he was the sole portfolio manager for the firm’s
health care-focused investment strategy.
About Societal CDMOSocietal
CDMO (NASDAQ: SCTL) is a bi-coastal contract development and
manufacturing organization (CDMO) with capabilities spanning
pre-Investigational New Drug (IND) development to commercial
manufacturing and packaging for a wide range of therapeutic dosage
forms with a primary focus in the area of small molecules. With an
expertise in solving complex manufacturing problems, Societal CDMO
is a leading CDMO providing therapeutic development, end-to-end
regulatory support, clinical and commercial manufacturing, aseptic
fill/finish, lyophilization, packaging and logistics services to
the global pharmaceutical market.
In addition to our experience in handling DEA
controlled substances and developing and manufacturing
modified-release dosage forms, Societal CDMO has the expertise to
deliver on our clients’ pharmaceutical development and
manufacturing projects, regardless of complexity level. We do all
of this in our best-in-class facilities, which total 145,000 square
feet, in Gainesville, Georgia and San Diego, California.
Societal CDMO: Bringing Science to Society. For
more information about Societal CDMO’s customer solutions, visit
societalcdmo.com.
Forward-Looking StatementsThis
press release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. The words "anticipate",
"believe", "correlate", "could", "estimate", “upcoming”, "expect",
"intend", "may", "plan", "predict", "project", "will" and similar
terms and phrases may be used to identify forward-looking
statements in this press release. Our operations involve risks and
uncertainties, many of which are outside our control, and any one
of which, or a combination of which, could materially affect our
results of operations and whether the forward-looking statements
ultimately prove to be correct. Factors that could cause the
company’s actual outcomes to differ materially from those expressed
in or underlying these forward-looking statements include, but are
not limited to, unstable market and macroeconomic conditions,
including any adverse impact on the customer ordering patterns or
inventory rebalancing or disruption in raw materials or supply
chain; demand for the company’s services, which depends in part on
customers’ research and development funding, their clinical plans
and the market success of their products; customers' changing
inventory requirements and manufacturing plans; customers and
prospective customers decisions to move forward with the company’s
manufacturing services; the average profitability, or mix, of the
products the company manufactures; the company’s ability to enhance
existing or introduce new services in a timely manner; the
Company’s ability to close its previously announced land sale
transaction on the anticipated timeline; fluctuations in the costs,
availability, and suitability of the components of the products the
company manufactures, including active pharmaceutical ingredients,
excipients, purchased components and raw materials, or the
company’s customers facing increasing or new competition; the
Company’s ability to collect on customers’ receivable balances; the
extent to which health epidemics and other outbreaks of
communicable diseases could disrupt our operations; and other risks
and uncertainties discussed in our filings with the Securities and
Exchange Commission at www.sec.gov. These forward-looking
statements are based on information currently available to us, and
we assume no obligation to update any forward-looking statements
except as required by applicable law.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Ryan D. Lake (CFO)
Societal CDMO
770-531-8365
ryan.lake@societalcdmo.com
Societal CDMO (NASDAQ:SCTL)
過去 株価チャート
から 6 2024 まで 7 2024
Societal CDMO (NASDAQ:SCTL)
過去 株価チャート
から 7 2023 まで 7 2024